Developing a vaccine to prevent Chlamydia trachomatis infections
Official title: Center for Biologically Inspired Nano-scaffolds for Mitigating Chlamydia trachomatis Pathogenesis
Funded at Lawrence Livermore National Security, LLC · NIH-10694893 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from Chlamydia, a common sexually transmitted infection, using advanced technology to make it more effective, so that everyone can have a better way to stay healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lawrence Livermore National Security, LLC NIH-funded |
| Lab location | 1 site (Livermore, United States) |
| Project start | August 8, 2019 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,878,172 |
| NIH project number | 5U19AI144184-05 |
| Project ID | NIH-10694893 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of Chlamydia trachomatis infections, particularly sexually active adults and adolescents.
✕Less likely to help
Patients who are not sexually active or those who have already been infected with Chlamydia trachomatis may not benefit from this research.
What this research studies
This research aims to create a vaccine for Chlamydia trachomatis, a common sexually transmitted infection that affects millions globally. The project involves a collaborative effort among various institutions to utilize innovative nano-formulated vaccine technologies. By engineering nanolipoprotein particles, the research seeks to enhance the delivery and effectiveness of the vaccine, addressing the challenges faced in previous vaccine development efforts. Patients may benefit from a new preventive measure against the health complications associated with this infection.
Why it matters
Potential benefit: If successful, this research could provide a much-needed vaccine to prevent Chlamydia trachomatis infections and their associated health complications.
How similar studies have gone: While there have been challenges in developing a Chlamydia vaccine, previous studies have shown promise with certain immunization strategies, making this approach both innovative and necessary.
Where this research is happening
-
Lawrence Livermore National Security, LLC
Livermore, United States Active
Researchers
- Principal investigator: Coleman, Matthew Adrian — Lawrence Livermore National Security, LLC
- Study coordinator: Coleman, Matthew Adrian
Related research
Other NIH-funded projects on the same topics.
-
Technology development for high-resolution biological imaging
A research project aims to create new imaging technologies to visualize biological molecules in action at near-atomic detail, potentially helping to uncover how they work and interact with drugs.
-
3D-printed human brain and blood-vessel model to reveal effects of traumatic brain injury
Researchers are building a 3D-printed human brain-and-blood-vessel model to see how traumatic brain injury leads to long-term brain damage and dementia.
-
Providing advanced isotopic analysis for biomedical research
This study is all about using a special method to measure tiny amounts of Carbon-14, which helps scientists better understand how our bodies work and how diseases develop, ultimately benefiting patients like you through improved research.
-
Creating a 3D model to study brain injuries and their effects
This study is creating a special 3D model of human brain blood vessels to help us learn more about how traumatic brain injuries affect people, with the hope that it will lead to better treatments for those who have experienced such injuries.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.